Compile Data Set for Download or QSAR
Report error Found 45 Enz. Inhib. hit(s) with all data for entry = 13211
Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767308(2-(5-bromo-3,6-dimethoxypyridin-2-yl)-N-(2-methoxy...)
Affinity DataKi:  0.350nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676134(US20240166618, Compound 36 | US20250270173, Compou...)
Affinity DataKi:  0.700nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767311(2-(5-hexyl-3,6-dimethoxypyridin-2-yl)ethan-1-amine...)
Affinity DataKi:  0.910nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50014997(DOHx | 1-(4-hexyl-2,5-dimethoxyphenyl)propan-2-ami...)
Affinity DataKi:  2.03nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674338(2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzy...)
Affinity DataKi:  2.52nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767320(1-(5-hexyl-3,6-dimethoxypyridin-2-yl)propan-2-amin...)
Affinity DataKi:  3.10nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674373(US20240166618, Compound 23 | US20240166618, Compou...)
Affinity DataKi:  5.41nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767312(2-(3,6-dimethoxy-5-(6,6,6-trifluorohexyl)pyridin-2...)
Affinity DataKi:  6.01nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767328(US20250270173, Compound 46)
Affinity DataKi:  6.31nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767294(2-(3,6-dimethoxy-5-pentylpyridin-2-yl)ethan-1-amin...)
Affinity DataKi:  6.32nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674354(US20240166618, Compound 6 | US20250270173, Compoun...)
Affinity DataKi:  7.10nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50005267(CHEMBL292821 | 2-(4-Bromo-2,5-dimethoxy-phenyl)-et...)
Affinity DataKi:  8.25nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767316(2-(5-(5-fluoropentyl)-3,6-dimethoxypyridin-2-yl)et...)
Affinity DataKi:  10.2nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767317(2-(3,6-dimethoxy-5-(4,4,4-trifluorobutyl)pyridin-2...)
Affinity DataKi:  13.6nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM81783(CAS_82830-44-2 | (+/-)-1-(2,5-DIMETHOXY-4-IODOPHEN...)
Affinity DataKi:  14.5nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50038369(2-(2,5-Dimethoxy-4-trifluoromethyl-phenyl)-ethylam...)
Affinity DataKi:  15.8nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50240788(2-(2,5-dimethoxy-4-ethylphenyl)ethylamine | 2-(4-E...)
Affinity DataKi:  16.7nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767313(2-(5-butyl-3,6-dimethoxypyridin-2-yl)ethan-1-amine...)
Affinity DataKi:  19.7nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767291(1-(3,6-dimethoxy-5-pentylpyridin-2-yl)propan-2-ami...)
Affinity DataKi:  26.2nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674356(US20240166618, Compound 7 | US20250270173, Compoun...)
Affinity DataKi:  26.3nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767318(2-(3,6-dimethoxy-5-propylpyridin-2-yl)ethan-1-amin...)
Affinity DataKi:  35.4nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767290(1-(3,6-dimethoxy-5-pentylpyridin-2-yl)butan-2-amin...)
Affinity DataKi:  40nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767327(US20250270173, Compound 45)
Affinity DataKi:  57.4nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676163(US20240166618, Compound 63i | US20250270173, Compo...)
Affinity DataKi:  58.6nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767305(2-(5-(ethylthio)-3,6-dimethoxypyridin-2-yl)ethan-1...)
Affinity DataKi:  82.8nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767296(2-(5-bromo-3,6-dimethoxypyridin-2-yl)ethan-1-amine...)
Affinity DataKi:  99.2nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767314(2-(5-(4-fluorobutyl)-3,6-dimethoxypyridin-2-yl)eth...)
Affinity DataKi:  103nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767315(2-(3,6-dimethoxy-5-(4,4,4-trifluorobutyl)pyridin-2...)
Affinity DataKi:  104nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767319(1-(3,6-dimethoxy-5-propylpyridin-2-yl)butan-2-amin...)
Affinity DataKi:  106nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767303(2-(5-ethyl-3,6-dimethoxypyridin-2-yl)ethan-1-amine...)
Affinity DataKi:  111nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767309(2-(5-cyclopropyl-3,6-dimethoxypyridin-2-yl)ethan-1...)
Affinity DataKi:  150nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767293(1-(5-bromo-3,6-dimethoxypyridin-2-yl)propan-2-amin...)
Affinity DataKi:  168nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767300(2-(5-chloro-3,6-dimethoxypyridin-2-yl)ethan-1-amin...)
Affinity DataKi:  264nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767298(1-(2,5-dimethoxy-6-pentylpyridin-3-yl)butan-2-amin...)
Affinity DataKi:  273nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767310(1-(5-cyclopropyl-3,6-dimethoxypyridin-2-yl)propan-...)
Affinity DataKi:  304nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767304(1-(5-ethyl-3,6-dimethoxypyridin-2-yl)propan-2-amin...)
Affinity DataKi:  322nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767306(1-(5-(ethylthio)-3,6-dimethoxypyridin-2-yl)propan-...)
Affinity DataKi:  344nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767301(1-(5-chloro-3,6-dimethoxypyridin-2-yl) propan-2-am...)
Affinity DataKi:  404nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767307(1-(5-(ethylthio)-3,6-dimethoxypyridin-2-yl)butan-2...)
Affinity DataKi:  649nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767299(1-(3,6-dimethoxy-5-pentylpyrazin-2-yl)butan-2-amin...)
Affinity DataKi:  693nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767295(2-(3,6-dimethoxy-5-methylpyridin-2-yl)ethan-1-amin...)
Affinity DataKi:  1.12E+3nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767292(1-(3,6-dimethoxy-5-methylpyridin-2-yl)propan-2-ami...)
Affinity DataKi:  1.17E+3nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM767302(1-(5-chloro-3,6-dimethoxypyridin-2-yl)butan-2-amin...)
Affinity DataKi:  1.20E+3nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674375(US20240166618, Compound 25 | US20250270173, Compou...)
Affinity DataKi:  1.47E+3nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50059891(3,4,5-trimethoxyphenylethylamine | 3,4,5-trimethox...)
Affinity DataKi:  1.74E+4nMAssay Description:The binding affinities of disclosed compounds at the ketanserin binding site of the 5-HT2A receptor were determined in radioligand binding experiment...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent